GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ValiRx PLC (LSE:VAL) » Definitions » Gross Profit

ValiRx (LSE:VAL) Gross Profit : £0.00 Mil (TTM As of Jun. 2023)


View and export this data going back to 2000. Start your Free Trial

What is ValiRx Gross Profit?

ValiRx's gross profit for the six months ended in Jun. 2023 was £0.00 Mil. ValiRx's gross profit for the trailing twelve months (TTM) ended in Jun. 2023 was £0.00 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. ValiRx's gross profit for the six months ended in Jun. 2023 was £0.00 Mil. ValiRx's Revenue for the six months ended in Jun. 2023 was £0.00 Mil. Therefore, ValiRx's Gross Margin % for the quarter that ended in Jun. 2023 was N/A%.

ValiRx had a gross margin of N/A% for the quarter that ended in Jun. 2023 => No sustainable competitive advantage

During the past 13 years, the highest Gross Margin % of ValiRx was 58.40%. The lowest was 6.02%. And the median was 30.68%.


ValiRx Gross Profit Historical Data

The historical data trend for ValiRx's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ValiRx Gross Profit Chart

ValiRx Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Gross Profit
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

ValiRx Semi-Annual Data
Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
Gross Profit Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of ValiRx's Gross Profit

For the Biotechnology subindustry, ValiRx's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ValiRx's Gross Profit Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ValiRx's Gross Profit distribution charts can be found below:

* The bar in red indicates where ValiRx's Gross Profit falls into.



ValiRx Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

ValiRx's Gross Profit for the fiscal year that ended in Dec. 2022 is calculated as

Gross Profit (A: Dec. 2022 )=Revenue - Cost of Goods Sold
=0 - 0
=0.00

ValiRx's Gross Profit for the quarter that ended in Jun. 2023 is calculated as

Gross Profit (Q: Jun. 2023 )=Revenue - Cost of Goods Sold
=0 - 0
=0.00

Gross Profit for the trailing twelve months (TTM) ended in Jun. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was £0.00 Mil.

Gross Profit is the numerator in the calculation of Gross Margin. (Note that if there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.)

ValiRx's Gross Margin % for the quarter that ended in Jun. 2023 is calculated as

Gross Margin % (Q: Jun. 2023 )=Gross Profit (Q: Jun. 2023 ) / Revenue (Q: Jun. 2023 )
=(Revenue - Cost of Goods Sold) / Revenue
=0.00 / 0
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


ValiRx  (LSE:VAL) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

ValiRx had a gross margin of N/A% for the quarter that ended in Jun. 2023 => No sustainable competitive advantage


ValiRx Gross Profit Related Terms

Thank you for viewing the detailed overview of ValiRx's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.


ValiRx (LSE:VAL) Business Description

Traded in Other Exchanges
Address
4 Barling Way, Eliot Park Innovation Centre, Nuneaton, GBR, CV10 7RH
ValiRx PLC is a UK-based biopharmaceutical company. It mainly engages in developing technologies and products in oncology therapeutics and diagnostics. The area of focus for the company is the treatment of cancer and associated biomarkers, specializing in epigenomic and genetic analysis. The company develops therapeutics across fields in oncology and has a portfolio of products in the pipeline which include GeneICE for Silencing Rebellious Genes, VAL201 for prostate cancer, NAV3 for the cancer screening test, and VAL401 for lung cancer.

ValiRx (LSE:VAL) Headlines

From GuruFocus

Valaris Publishes Sustainability Report

By Business Wire Business Wire 12-15-2022

Valaris Announces Drillship Contract Award

By Business Wire 07-31-2023

Valaris Reports Second Quarter 2023 Results

By Business Wire 08-02-2023

Valaris Provides Fleet Status Report

By Business Wire 08-02-2023

Valaris Announces Contract Award for Drillship VALARIS DS-12

By Business Wire Business Wire 11-21-2022

Valaris Provides Quarterly Fleet Status Report

By Business Wire Business Wire 10-31-2022

Oak Hill Advisors LP Reduces Stake in Valaris Ltd

By GuruFocus Research 08-10-2023